MDNA vs. ONC, SVA, TH, AEZS, HBP, FRX, HTL, CRDL, CPH, and QIPT
Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include Oncolytics Biotech (ONC), Sernova (SVA), Theratechnologies (TH), Aeterna Zentaris (AEZS), Helix BioPharma (HBP), Fennec Pharmaceuticals (FRX), Hamilton Thorne (HTL), Cardiol Therapeutics (CRDL), Cipher Pharmaceuticals (CPH), and Quipt Home Medical (QIPT). These companies are all part of the "medical" sector.
Oncolytics Biotech (TSE:ONC) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
Oncolytics Biotech received 108 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. Likewise, 75.38% of users gave Oncolytics Biotech an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.
In the previous week, Oncolytics Biotech had 9 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 10 mentions for Oncolytics Biotech and 1 mentions for Medicenna Therapeutics. Oncolytics Biotech's average media sentiment score of 0.00 beat Medicenna Therapeutics' score of -0.12 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.
6.7% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 7.9% of Medicenna Therapeutics shares are held by institutional investors. 3.9% of Oncolytics Biotech shares are held by insiders. Comparatively, 23.7% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Oncolytics Biotech has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Oncolytics Biotech's return on equity of -59.47% beat Medicenna Therapeutics' return on equity.
Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
Oncolytics Biotech currently has a consensus price target of C$6.00, indicating a potential upside of 277.36%. Given Medicenna Therapeutics' higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Medicenna Therapeutics.
Summary
Oncolytics Biotech and Medicenna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Medicenna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicenna Therapeutics Competitors List
Related Companies and Tools
